Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (253)	7/23/2001 12:34:10 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 370

Vion Begins Triapine Phase 2 Clinical Trial Dow Jones Newswires NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION) began the Phase II clinical trial of its investigational anti-cancer agent, Triapine. In a press release Monday, the biotechnology company said the study will evaluate the activity of Triapine in patients with acute and chronic leukemia. Vion said in preclinical studies, Triapine inhibits DNA synthesis, slows, or stops cancer cell division and disrupts repair of DNA damage caused by several standard anti-cancer agents. In Phase I clinical trials, Vion said Triapine was "well tolerated" in patients with advanced and treatment-resistant solid tumors. Studies also found that Triapine could be administered every other week. The Phase II will begin at the Greenebaum Cancer Center of the University of Maryland. Vion shares closed Friday's Nasdaq-trading at $7.10, up 25 cents, or 5.2%. Company Web site: vionpharm.com